This report from Life Science Intelligence provides the latest market data for the Global Cardiac Ablation Devices Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for cardiac ablation devices is expected to reach an estimated $1.6 billion in 2020 and is projected to increase at a CAGR (2020-2024) of 15.6%. Product segments covered by this report include radiofrequency ablation and cryoablation catheters for the elimination of aberrant conduction pathways in the heart, which are primarily employed for the treatment of arrhythmias.
This report covers the impact of COVID-19 on the cardiac ablation devices market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Abbott, Boston Scientific, Johnson & Johnson (Biosense), and others. The report provides insights into trends, drivers, and limiters of the cardiac ablation devices market, as well as highlights potential opportunities.
Cardiac ablation procedure volumes witnessed a minor decline due to the COVID-19 pandemic. The decline in procedures was very minimal and is expected to rebound and reach pre-COVID-19 levels in the first half of 2021.
J&J (Biosense) is the market leader in cardiac ablation technology, with an estimated market share of 60%.
Atrial fibrillation is the most common form of arrhythmia. In the US, the prevalence of atrial fibrillation is estimated to range from 2.7 million to 6.1 million individuals. It is estimated that more than 33.5 million people worldwide are affected globally by atrial fibrillation.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
